

APA001Hu01 100µg
Active Active Inhibin Beta A (INHbA)
Organism Species: *Homo sapiens* (Human)
Instruction manual

FOR RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

1th Edition (Apr, 2016)

[PROPERTIES]

Source: Prokaryotic expression.

Host: *E. coli*

Residues: Gly311~Ser426

Tags: N-terminal His-tag

Purity: >95%

Endotoxin Level: <1.0EU per 1µg (determined by the LAL method).

Buffer Formulation: 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl and 5% trehalose.

Applications: Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

Predicted isoelectric point: 6.8

Predicted Molecular Mass: 14.2kDa

Accurate Molecular Mass: 15kDa as determined by SDS-PAGE reducing conditions.

[USAGE]

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

[SEQUENCE]

```
GLECDGKVINI CCKKQFFVSF KDIGWNDWII APSGYHANYC  
EGECPSHIAG TSGSSLSFHS TVINHYRMRG HSPFANLKSC CVPTKLRPMS  
MLYYDDGQNI IKKDIQNMIV EECGCS
```

[ACTIVITY]

Activin A (ACVA) is a dimer composed of two identical called activin β A. Activin β A and β B are identical to the two beta subunits of inhibin. Activin enhances FSH biosynthesis and secretion, and participates in the regulation of the menstrual cycle. Many other functions have been found to be exerted by activin, including roles in cell proliferation, differentiation, apoptosis, metabolism, homeostasis, immune response, wound repair, and endocrine function. Besides, Activin A Receptor Type I (ACVR1) has been identified as an interactor of ACVA, thus a binding ELISA assay was conducted to detect the interaction of recombinant human ACVA and recombinant human ACVR1. Briefly, ACVA were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 μ L were then transferred to ACVR1-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-ACVA pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50 μ L stop solution to the wells and read at 450nm immediately. The binding activity of ACVA and ACVR1 was shown in Figure 1, and this effect was in a dose dependent manner.




Figure 1. The binding activity of ACVA with ACVR1.

[IDENTIFICATION]




Figure 2. SDS-PAGE

Sample: Active recombinant INHbA, Human




Figure 3. Western Blot

Sample: Recombinant INHbA, Human;

Antibody: Rabbit Anti-Human INHbA Ab (PAA001Hu01)

[IMPORTANT NOTE]

The kit is designed for in vitro and research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.